Integral Health Asset Management, LLC
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.64B2026 Q3+ $12.2M options (notional, not included)
Positions97
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.43.2%
What Changed This Quarter?
Top Holdings
RVMD
Revolution Medicines
7.9%
INSM
Insmed
7.8%
EWTX
Edgewise Therapeutics
5.9%
CYTK
Cytokinetics
4.4%
MRK
Merck
4.0%
SRRK
Scholar Rock
3.7%
CNC
Centene
2.8%
AXSM
Axsome Therapeutics
2.8%
New / Increased
40 new · 12 increased
AMGNNEW
Amgen
1.9%
INCYNEW
Incyte
1.2%
ONCNEW
Beone Medicines
1.1%
BDXNEW
Becton Dickinson
1.1%
EHCNEW
Encompass Health
0.9%
CNC
Centene
2.8%
+150.0%
SRRK
Scholar Rock
3.7%
+67.3%
EWTX
Edgewise Therapeutics
5.9%
+20.0%
Reduced / Exited
26 reduced · 35 sold out
RVMD
Revolution Medicines
7.9%
-33.3%
CAH
Cardinal Health
1.4%
-66.7%
EW
Edwards Lifesciences
1.0%
-68.0%
DGX
Quest Diagnostics
0.8%
-72.5%
CVS
CVS Health
1.3%
-54.5%
RVMDPUTEXIT
Revolution Medicines
2.2%
ALHCEXIT
Alignment Healthcare
1.9%
ABTEXIT
Abbott Laboratories
1.4%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.